Literature DB >> 20422454

Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases.

Tjeerd S Aukema1, Renato A Valdés Olmos, Michel W J M Wouters, W Martin C Klop, Bin B R Kroon, Wouter V Vogel, Omgo E Nieweg.   

Abstract

BACKGROUND: The aims of this prospective study were to determine the diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and brain MRI in melanoma patients with palpable lymph node metastases and to assess the impact of these imaging modalities on their management.
MATERIALS AND METHODS: Between October 2006 and March 2009, PET/CT and brain MRI were performed in 70 melanoma patients with palpable nodal lymph node metastases and without evidence of systemic dissemination after physical examination. Hypermetabolic PET/CT lesions were examined by histology or cytology or were imaged further and followed if no pathology confirmation could be obtained.
RESULTS: PET/CT findings changed the intended regional node dissection in 26 patients (37%). PET/CT was false negative in 4 patients (6%) and false positive in 1 (1%). This resulted in a sensitivity of 87%, specificity of 98%, accuracy of 93%, positive predictive value of 96%, and negative predictive value of 91%. MRI revealed brain metastases in 5 patients (7%). The overall survival of patients without additional lesions on PET/CT was 84% after 2 years, which was better than the 56% in patients with additional metastases (P < .001).
CONCLUSIONS: PET/CT has an 87% sensitivity and 98% specificity in the detection of other metastases in melanoma patients with palpable lymph node involvement. PET/CT leads to a change in the planned regional node dissection in 37% of the patients in this study. MRI revealed brain metastases in 5 patients (7%). PET/CT findings correlate with survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422454     DOI: 10.1245/s10434-010-1088-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.

Authors:  Amanda K Raymond; Georgia M Beasley; Gloria Broadwater; Christina K Augustine; James C Padussis; Ryan Turley; Bercedis Peterson; Hilliard Seigler; Scott K Pruitt; Douglas S Tyler
Journal:  J Am Coll Surg       Date:  2011-04-13       Impact factor: 6.113

Review 2.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 3.  Melanoma and nuclear medicine.

Authors:  Andrés Perissinotti; Sergi Vidal-Sicart; Omgo Nieweg; Renato Valdés Olmos
Journal:  Melanoma Manag       Date:  2014-09-05

4.  Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma.

Authors:  Christy Y Chai; Jonathan S Zager; Margaret M Szabunio; Suroosh S Marzban; Alec Chau; Robert M Rossi; Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2011-12-23       Impact factor: 5.344

5.  Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma.

Authors:  Maria Danielsen; Andreas Kjaer; Max Wu; Lea Martineau; Mehdi Nosrati; Stanley Pl Leong; Richard W Sagebiel; James R Miller; Mohammed Kashani-Sabet
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-09-22

6.  PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.

Authors:  Thomas Pfluger; Henriette Ingrid Melzer; Vera Schneider; Christian La Fougere; Eva Coppenrath; Carola Berking; Peter Bartenstein; Mayo Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

7.  A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.

Authors:  Georgia M Beasley; Colin Parsons; Gloria Broadwater; M Angelica Selim; Suroosh Marzban; Amy P Abernethy; April K S Salama; Edward A Eikman; Terence Wong; Jonathan S Zager; Douglas S Tyler
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

Review 8.  F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.

Authors:  Milly A Schröer-Günther; Robert F Wolff; Marie E Westwood; Fülöp J Scheibler; Christoph Schürmann; Brigitta G Baumert; Stefan Sauerland; Jos Kleijnen
Journal:  Syst Rev       Date:  2012-12-13

9.  Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience.

Authors:  Manil Subesinghe; Maria Marples; Andrew F Scarsbrook; Jonathan T Smith
Journal:  Insights Imaging       Date:  2013-09-10

10.  Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging.

Authors:  Christiaan Schiepers; Magnus Dahlbom
Journal:  Eur Radiol       Date:  2010-12-21       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.